MedTrace Logo

Assessing the Safety and Bioactivity of SG1002 in Heart Failure Patients

NCT02278276 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-11-26

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and benefits of SG1002, including overcoming deficits in circulating hydrogen sulfide and nitrite found in heart failure patients, with secondary endpoints focused on improving clinical endpoints.

Conditions

Interventions

DRUG

sodium polysulthionate

Bioavailable composition of α-sulfur

DRUG

Placebo

400 mg capsules containing placebo

Sponsors & Collaborators

  • Sulfagenix Australia Pty Ltd.

    lead INDUSTRY

Principal Investigators

  • Tony Giordano, PhD · Sulfagenix Australia Pty Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-04-30
Completion
2018-07-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02278276 on ClinicalTrials.gov